DK1778860T3 - Fremgangsmåde til bestemmelse af styrke, specificiteten og toksiciteten af hæmapoietisk prostaglandin D2 systase - Google Patents

Fremgangsmåde til bestemmelse af styrke, specificiteten og toksiciteten af hæmapoietisk prostaglandin D2 systase

Info

Publication number
DK1778860T3
DK1778860T3 DK05781699T DK05781699T DK1778860T3 DK 1778860 T3 DK1778860 T3 DK 1778860T3 DK 05781699 T DK05781699 T DK 05781699T DK 05781699 T DK05781699 T DK 05781699T DK 1778860 T3 DK1778860 T3 DK 1778860T3
Authority
DK
Denmark
Prior art keywords
potency
specificity
toxicity
prostaglandin
systasis
Prior art date
Application number
DK05781699T
Other languages
Danish (da)
English (en)
Inventor
Yang Cao
Jeffrey S Sabol
Stephen Ayers
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1778860T3 publication Critical patent/DK1778860T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ecology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK05781699T 2004-07-30 2005-07-28 Fremgangsmåde til bestemmelse af styrke, specificiteten og toksiciteten af hæmapoietisk prostaglandin D2 systase DK1778860T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59250104P 2004-07-30 2004-07-30
PCT/US2005/026945 WO2006015195A1 (en) 2004-07-30 2005-07-28 Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase

Publications (1)

Publication Number Publication Date
DK1778860T3 true DK1778860T3 (da) 2008-05-13

Family

ID=35115717

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05781699T DK1778860T3 (da) 2004-07-30 2005-07-28 Fremgangsmåde til bestemmelse af styrke, specificiteten og toksiciteten af hæmapoietisk prostaglandin D2 systase

Country Status (15)

Country Link
US (1) US20070259384A1 (de)
EP (1) EP1778860B1 (de)
JP (1) JP2008507980A (de)
KR (1) KR20070046830A (de)
CN (1) CN1993479A (de)
AT (1) ATE384136T1 (de)
AU (1) AU2005267920A1 (de)
BR (1) BRPI0512645A (de)
CA (1) CA2575523A1 (de)
DE (1) DE602005004420T2 (de)
DK (1) DK1778860T3 (de)
ES (1) ES2297753T3 (de)
IL (1) IL180837A0 (de)
MX (1) MX2007000043A (de)
WO (1) WO2006015195A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2286221A4 (de) 2008-05-13 2011-07-06 Cayman Chem Co Verfahren zum testen von verbindungen oder mitteln auf ihre fähigkeit zur verschiebung starker liganden der hämatopoietischen prostaglandin-d-synthase
CN111549000B (zh) * 2020-06-18 2022-07-29 中国医学科学院整形外科医院 一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3600847B2 (ja) * 1996-06-05 2004-12-15 財団法人大阪バイオサイエンス研究所 ヒトの造血器型プロスタグランジンd合成酵素をコードするdna
GB0229244D0 (en) * 2002-08-16 2003-01-22 Aventis Pharma Inc Method for assaying compounds for inhibition of the activity of prostaglandin synthase
US20060229324A1 (en) * 2002-10-03 2006-10-12 Akiko Itai Quinazolin-4-one derivatives

Also Published As

Publication number Publication date
CN1993479A (zh) 2007-07-04
WO2006015195A1 (en) 2006-02-09
CA2575523A1 (en) 2006-02-09
DE602005004420T2 (de) 2009-01-08
ES2297753T3 (es) 2008-05-01
DE602005004420D1 (de) 2008-03-06
IL180837A0 (en) 2007-06-03
EP1778860B1 (de) 2008-01-16
BRPI0512645A (pt) 2008-03-25
ATE384136T1 (de) 2008-02-15
US20070259384A1 (en) 2007-11-08
AU2005267920A1 (en) 2006-02-09
KR20070046830A (ko) 2007-05-03
MX2007000043A (es) 2007-03-27
JP2008507980A (ja) 2008-03-21
EP1778860A1 (de) 2007-05-02
WO2006015195A8 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
UY29479A1 (es) Inhibidores de adn-pk
UA94412C2 (en) Glutamate aggrecanase inhibitors
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
UY29612A1 (es) Compuestos quimicos ii
ATE400567T1 (de) Kinaseinhibitoren
EA200601701A1 (ru) Ингибиторы дипептидилпептидазы
NO20080761L (no) Acykliske Ikur inhibitorer
NO20071309L (no) Fremgangsmate for ekspansjon
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
SV2006002232A (es) Inhibidores bace ref. x-16940
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
DK1491540T3 (da) Intermediater, der er anvendelige til syntese af pyridazinon-aldosereduktase inhibitorer
WO2007120699A3 (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals
SV2006002001A (es) Inhibidores de quinasa ref. x - 16437
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
TR200705187T1 (tr) 2-Kromen hazırlanması için yeni yöntemler
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
DE112005003431A5 (de) Neuartige Inhibitoren der Lysyloxidase
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
NO20080468L (no) Diazepinokinoliner, synteser av disse samt intermediater
SE0103710D0 (sv) Compounds
DE60336475D1 (de) Ät
NO20082185L (no) Heterocykliske CETP-inhibitorer
DK1778860T3 (da) Fremgangsmåde til bestemmelse af styrke, specificiteten og toksiciteten af hæmapoietisk prostaglandin D2 systase
DE602005023528D1 (de) Piperidinderivate als prodrugs von kaliumkanalinhibitoren